ACEN completes transition to 100% renewable energy
MANILA, Philippines, Dec. 29, 2025 /PRNewswire/ -- ACEN has reached a defining milestone in its transformation journey, having achieved 100% renewable energy generation across its portfolio earlier this year. The milestone underscores a strategic...
Highway Holdings Plans to Acquire 51% of Regent-Feinbau Adermann GmbH
HONG KONG, Dec. 23, 2025 /PRNewswire/ -- Highway Holdings Limited (Nasdaq: HIHO, the "Company" or "Highway Holdings") today announced it has signed a letter of intent ("LOI") with LeMALe Beteiligungs-GmbH ("LeMaLe" or "Seller") to acquire 51% of...
CDNetworks Successfully Mitigates a 1.01 Tbps DDoS Attack
SINGAPORE, Dec. 10, 2025 /PRNewswire/ -- CDNetworks, the APAC-leading network to deliver edge as a service, has successfully mitigated a 1.01 terabits per second (Tbps) DDoS attack targeting a major software download platform on October 11, 2025....
Traveloka and Singapore Tourism Board launch regional campaign to inspire spontaneous weekend getaways to Singapore
SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- Traveloka, Southeast Asia's leading travel platform, and the Singapore Tourism Board (STB) strengthen their partnership with the launch of a new regional marketing campaign targeting young travellers titled 'A...
Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
NANJING, China, Dec. 8, 2025 /PRNewswire/ -- From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology ("ASH") was held in Orlando, Florida, USA. Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company",...
Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated,...
Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid...
The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
CorrectSequence Therapeutics' CS-121 Completed Dosing of First Chylomicronemia Patient, Demonstrating Excellent Safety and Significant Efficacy SHANGHAI, Nov. 6, 2025 /PRNewswire/ -- On November 6, 2025, Shanghai, China, CorrectSequence Therapeutics...
AMTD Digital subsidiary TGE's Hotels Portfolio Anticipated to Exceed 1,000 Rooms and double its Revenue
PARIS and NEW YORK and SINGAPORE, Nov. 3, 2025 /PRNewswire/ -- AMTD Group Inc. ("AMTD" or the "Group"), AMTD IDEA Group ("AMTD IDEA Group") (NYSE: AMTD; SGX: HKB) and The Generation Essentials Group ("TGE", NYSE: TGE), a subsidiary of AMTD Digital...
Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection
BEIJING and GOTHENBURG, Sweden, Oct. 24, 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016...